New Tetromycin Derivatives with Anti-Trypanosomal and Protease Inhibitory Activities † by Pimentel-Elardo, Sheila M. et al.
Mar. Drugs 2011, 9, 1682-1697; doi:10.3390/md9101682 
 
Marine Drugs 
ISSN 1660-3397 
www.mdpi.com/journal/marinedrugs 
Article 
New Tetromycin Derivatives with Anti-Trypanosomal and 
Protease Inhibitory Activities 
† 
Sheila M. Pimentel-Elardo 
1,‡,*, Verena Buback 
2, Tobias A.M. Gulder 
3,§, Tim S. Bugni 
4,||,  
Jason Reppart 
4, Gerhard Bringmann 
3, Chris M. Ireland 
4, Tanja Schirmeister 
2,¶ and  
Ute Hentschel 
1 
1  Julius-von-Sachs Institute for Biological Sciences, University of Würzburg, Julius-von-Sachs-Platz 3, 
Würzburg 97082, Germany; E-Mail: ute.hentschel@uni-wuerzburg.de 
2  Institute for Pharmacy and Food Chemistry, Am Hubland, Würzburg 97074, Germany;  
E-Mails: verena.buback@uni-wuerzburg.de (V.B.); schirmei@pharmazie.uni-wuerzburg.de (T.S.) 
3  Institute of Organic Chemistry, University of Würzburg, Am Hubland, Würzburg 97074, Germany; 
E-Mails: tgulder@uni-bonn.de (T.A.M.G.); bringman@chemie.uni-wuerzburg.de (G.B.) 
4  Department of Medicinal Chemistry, University of Utah, Salt Lake City, UT 84112, USA;  
E-Mails: tbugni@pharmacy.wisc.edu (T.S.B.); jreppart@gmail.com (J.R.); 
cireland@pharm.utah.edu (C.M.I.) 
†  This work is dedicated to Johannes F. Imhoff on the occasion of his 60th birthday. 
‡  Current address: Department of Biochemistry and Biomedical Sciences, Health Sciences Centre, 
McMaster University, 1200 Main St. W. Hamilton, ON L8N 3Z5, Canada. 
§  Current address: Kekulé Institute of Organic Chemistry and Biochemistry, University of Bonn, 
Gerhard-Domagk-Str. 1, Bonn 53121, Germany. 
||  Current address: School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705, USA. 
¶  Current address: Institute of Pharmacy and Biochemistry, University of Mainz, Staudinger Weg 5, 
Mainz 55099, Germany. 
*  Author to whom correspondence should be addressed; E-Mail: elardos@mcmaster.ca;  
Tel.: +1-905-525-9140 (ext. 27334). 
Received: 25 July 2011; in revised form: 9 September 2011 / Accepted: 16 September 2011 /  
Published: 26 September 2011  
 
Abstract: Four new tetromycin derivatives, tetromycins 1–4 and a previously known one, 
tetromycin B (5) were isolated from Streptomyces axinellae Pol001
T cultivated from the 
Mediterranean sponge Axinella polypoides. Structures were assigned using extensive 1D 
and 2D NMR spectroscopy as well as HRESIMS analysis. The compounds were tested for 
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antiparasitic activities against Leishmania major and Trypanosoma brucei, and for protease 
inhibition against several cysteine proteases such as falcipain, rhodesain, cathepsin L, 
cathepsin B, and viral proteases SARS-CoV M
pro, and PL
pro. The compounds showed 
antiparasitic activities against T. brucei and time-dependent inhibition of cathepsin L-like 
proteases with Ki values in the low micromolar range. 
Keywords: tetromycin; anti-trypanosomal; protease inhibition; Streptomyces axinellae; 
marine sponge 
 
1. Introduction 
Protozoan diseases such as malaria, leishmaniasis, and African and South American trypanosomiasis 
afflict millions of people particularly in many tropical and subtropical countries. Coronaviruses are 
also important pathogens that mainly cause respiratory and enteric diseases in humans. For example, 
SARS-CoV causes severe acute respiratory syndrome (SARS) resulting in the epidemic in 2002–2003 
with more than 8000 death cases worldwide [1]. The increasing resistance to current therapies and the 
toxicities of existing drugs aggravates the prevalence of these infectious diseases. These issues thus 
necessitate the need for alternative therapies. A promising strategy is to develop new drugs targeting 
the parasites’ cysteine proteases that are crucial for their growth, differentiation and pathogenicity. 
Examples of these proteolytic enzymes are rhodesain from Trypanosoma rhodesiense, falcipain from 
Plasmodium falciparum, and cysteine cathepsins from Leishmania spp. [2]. Moreover, the coronavirus 
main protease (M
pro, also named 3C-like protease 3CL
pro) as well as the papain-like protease   
(SARS-CoV PL
pro) are also considered to be major targets for new antiviral drugs against SARS and 
other coronavirus infections [3]. 
Marine sponges are the most prolific sources of bioactive metabolites in the marine environment. 
More than 5300 different natural products have so far been isolated from marine sponges and their 
associated bacteria and more than 200 new metabolites are reported from sponges annually [4]. Owing 
to their filter-feeding capacity and to the frequent presence of massive amounts of microbial symbiotic 
consortia in the mesohyl tissues, sponges are also rich sources of microorganisms, many of which 
produce interesting bioactivities [5,6]. Cultivation efforts have focused particularly on the 
actinomycetes, as this taxonomic clade is responsible for the production of about half of the discovered 
antibiotics to date [7–9]. We have recently described the isolation of a new actinomycete species, 
Streptomyces axinellae type strain Pol001 cultivated from the Mediterranean sponge, 
Axinella polypoides  [10]. Here, the isolation of new tetromycin derivatives with unprecedented 
inhibitory activities against several clinically important cysteine proteases is reported. The choice to 
use cysteine proteases as possible target enzymes is based on the tetronic acid moiety which is part of 
all the isolated metabolites. Due to its lactone ring with the double bond activated for nucleophilic 
attack by its electron withdrawing substituents, this moiety is predestined to inhibit cysteine proteases. Mar. Drugs 2011, 9  
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2. Results and Discussion 
2.1. Structure Elucidation 
Streptomyces axinellae Pol001
T was grown on MS [11] agar and the secondary metabolites were 
extracted with ethyl acetate. HPLC fractionation yielded five compounds, tetromycins 1–4 (1–4), and 
tetromycin B (5) [12]. HRESIMS and extensive 1D and 2D NMR analysis (Table 1) suggested that the 
compounds were new constitutional isomers with several tetromycins that had been previously isolated 
from a Streptomyces sp. strain MK67-CF9 [13]. Tetromycin 1 displayed a pseudo-molecular ion in the 
positive ESIMS spectrum at m/z 910.4388 [M + Na]
+ that corresponded to a molecular formula of 
C50H65NO13 and was isomeric with tetromycin C5 [13]. Tetromycin 2 was observed to have a molecular 
ion in the positive ESIMS spectrum at m/z 911.4232 [M + Na]
+ corresponding to a molecular formula of 
C50H64O14 which was isomeric with tetromycin C1 [13] and tetromycin 4 with m/z 897.4066 [M + Na]
+ 
matching a molecular formula of C49H62O14 which was isomeric with tetromycin C2 [13].  
Table 1. 
13C and 
1H NMR data of tetromycins 1–4 in acetone-d6. 
Posn. 
1  2  3  4 
δC  mult  δH  mult, (JH-H)  δC  mult  δH  mult, (JH-H)  δC  mult δH  mult, (JH-H)  δC  mult  δH  mult, (JH-H)
1  167.4  C  168.4  C     174.8 C  169.0  C       
2  96.8 C  99.6 C      96.8 C  99.1 C     
3  206.3 C  204.5 C      205.4 C  204.6 C     
4  52.4 C  52.7 C      52.6 C  52.6 C     
4′ 15.8  CH3 1.52  s    16.0 CH3 1.52 s  15.4 CH3 1.54 s  15.6 CH3 1.52 s 
5  57.5  CH 3.40  s    57.4  CH 3.49 s  57.5 CH  3.35 s  57.0 CH  3.51 s 
6  135.4 C  135.9 C      135.7 C  136.1 C     
6′ 21.8  CH3 1.29  s    22.0 CH3 1.53 s  22.9 CH3 1.39 s  25.3 CH3 1.48 s 
7  131.5 CH  5.09 d  (8.2)  131.5 CH  5.13 d  (6.6)  130.6 CH  5.00 d (9.2)  131.1  CH  5.14 d (7.1) 
8 32.9  CH2 2.27  m  34.2 CH2 2.28 m  34.1 CH2 2.27 m  33.8 CH2 2.27 m 
9 36.3  CH2 2.29  m  35.5 CH2 2.32 m  40.4 CH2 2.23 m  40.6 CH2 2.38 m 
10  132.1 C  131.1 C      131.6 C  131.4 C     
10′ 22.0  CH3 1.31  s    21.8 CH3 1.33 s  22.9 CH3 1.31 s  21.7 CH3 1.35 s 
11  123.2 CH  6.17 s    123.1 CH  6.08 s  122.9 CH  6.11 s  122.8 CH  6.15 s 
12  46.4 C  46.2 C      42.0 C  2.07 br  46.2 C     
12′ 22.8  CH3 1.52  s    23.0 CH3 1.50 s      22.9 CH3 1.50 s 
13  145.7 CH  6.92 s    146.6 CH  6.92 s  138.6 CH  6.67 s  146.8 CH  6.92 s 
14  132.1 C  126.0 C      135.1 C  125.7 C     
14′  168.1 C  167.7 C      167.5 C  168.5 C     
15  27.8  CH 2.97  m  28.0  CH 2.93  m 27.8 CH  2.95 m  28.0  CH  2.91 m 
15′ 13.1  CH3 1.33  m  13.4 CH3 1.34 m  13.8 CH3 1.30 m  13.2 CH3 1.32 m 
16 32.9  CH2  1.79 br  33.23 CH2 1.74 br  27.8 CH2 1.58 br  33.1 CH2 1.69 br 
   2.71  dd (14.8, 7.9)     2.65 dd (14.4, 7.9)    2.23 m     2.65 dd (14.6, 7.9)
17  85.9 C  85.6 C      82.7 C  85.6 C     
18  198.6 C  199.3 C      202.1 C  200.3 C     
19  55.7  CH 3.82  br  55.5  CH 3.67 br 42.1 CH  3.71 br  42.1  CH  3.60 br 
20  124.8 CH  4.90 s  125.6 CH  4.93 s  141.5 C  125.8 CH  4.92 s Mar. Drugs 2011, 9  
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Table 1. Cont. 
20′        14.3 CH3  1.48 s       
21  140.9 C  140.2 C      120.3 CH  4.95 d  (2.3)  140.4 C     
21′ 19.2  CH3 1.69  s    19.2 CH3 1.69 s      18.9 CH3 1.69 s 
22 39.59  CH2 2.29  m  39.9 CH2 2.20 m  34.1 CH2 2.32 m  39.7 CH2 2.26 m 
      1.94  m     1.97 m     1.19 m     1.95 m 
23  84.4  CH  3.33  dt (10.4, 4.8)  85.0  CH  3.36 dt (10.2, 4.8)  84.56 CH  3.41 dt (10.4, 4.8)  84.9  CH  3.39 dt (10.5, 4.8)
24 46.2  CH  1.94  m  46.7  CH  1.90 m 46.8 CH  1.93 m  46.5  CH  1.90 m 
25 35.3  CH2 1.34  br  35.6 CH2 1.31 br  36.4 CH2 1.52 br  37.8 CH2 1.54 br 
26 42.6  CH  2.08  br  43.1  CH  2.09 br 37.9 CH  2.07 br  42.9  CH  2.09 br 
26′ 22.8  CH3 0.68  d  (5.6)  23.1 CH3 0.70 d  (5.1)  22.7 CH3 0.68 d  (5.9)  22.9 CH3 0.69 d  (5.7) 
27  103.6 CH  4.67 d  (7.9)  103.4 CH  4.77 d  (7.9)  103.1 CH  4.81 d (7.9)  103.2  CH  4.81 d (7.9) 
28  70.6  CH  3.79  m  72.4  CH  3.54 dd (7.9, 2.9)  71.9 CH  3.55 dd (7.9, 3.1)  72.0  CH  3.54 dd (7.9, 3.1) 
29 73.8  C      70.5  CH  4.33 br  69.6 CH 4.38 br  69.7  CH 4.39 br 
29′ 19.01  CH3  1.22  s                   
30  58.4  CH  3.90  d (10.0)  76.1  CH  4.68 dd (9.8, 2.4)  76.8 CH  4.75 dd (9.8, 2.8)  76.8  CH  4.76 dd (9.8, 2.7) 
31 75.8  CH  3.33  m  67.6  CH  4.03 m 67.3 CH  4.17 m  67.2  CH  4.18 m 
31′ 23.7  CH3 1.32  d  (7.3)  18.2 CH3 1.31 d  (7.21)  18.4 CH3 1.24 d  (6.2)  18.3 CH3 1.25 d  (6.2) 
32  170.6  C     164.8  C     171.1 C     170.4  C    
33  113.1  C     108.0  C     106.2 C     106.2  C    
34  139.1  C     144.0  C     144.5 C     144.6  C    
34′ 22.6  CH3  2.5 s  24.6 CH3 2.56 s  24.5 CH3 2.54 s  24.3 CH3 2.55 s 
35  110.0 CH  6.33 s  111.8 CH  6.36 br  d  111.7 CH  6.37 d (2.3)  111.7  CH  6.37 d (2.5) 
36  161.9  C     162.6  C     165.1 C     165.8  C    
36′        55.9  CH3  3.83 s             
37 99.9  CH  6.33  s  97.0  CH  6.45  br  d  99.5 CH  6.34 d (2.3)  99.6  CH  6.34 d (2.5) 
38  162.9  C     158.7  C     166.0 C     165.3  C    
38′ 55.5  CH3 3.78  s  55.9 CH3 3.82 s  55.8 CH3 3.83 s  55.7 CH3 3.83 s 
The IR spectra of tetromycins 1–4 showed the expected absorption bands for hydroxy groups 
(~3200 cm
−1), acid functions (~2800 cm
−1), carbonyl groups (~1700 cm
−1), conjugated carbonyl groups 
(~1640 cm
−1), C–C-double bonds (~1300 cm
−1), and aromatic rings (~1600 cm
−1). The presence of these 
functional groups was further supported by the 
1H, 
13C and DEPT NMR data. The carbon-proton 
connectivities were unambiguously assigned by HSQC experiments. In all four compounds, the 
13C 
NMR indicated the presence of a two-times hydroxy/alkoxy-substituted aromatic moiety made of 
carbons C33–38. The corresponding signals in the 
1H NMR spectra showed only two aromatic protons 
(H35; H37) in meta-position to each other of the aromatic ring (see Table 1 for shifts, multiplicity, and 
coupling constants). HMBC correlations of the methyl group protons H34′ to the carbonyl C32 and to 
C33–C35 of the aromatic ring confirmed an additional ortho-substitution pattern. COSY interactions 
of H34′ to only one of the aromatic protons (H35) left C36 and C38 open for further substitution. 
Aromatic carbon shifts of C36 and C38 at ~160 ppm indicated the hydroxy or alkoxy substituents to be 
located at these positions. In tetromycins 2, 3, and 4, the hydroxy group at C38 is methylated, as 
evident from the correlations between methoxy group protons H38′ and C38 in the HMBC spectrum. 
By contrast, compound 1 is hydroxylated at C38. C36 carries a methoxy group in compounds 1 and 2 
and hydroxy groups in 3 and 4 as clearly indicated by HMBC, 
13C and 
1H data (Figure 1). Mar. Drugs 2011, 9  
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Figure 1. Selected 2D NMR correlations in tetromycin 4. 
 
HMBC correlations of H30 to C32 in tetromycins 1–4 revealed the connectivity of the aromatic ring 
to a pyran fragment via an ester or amide bond, respectively (Figure 1). The substitution pattern of this 
moiety was unambiguously established by HMBC and ROESY data. The connectivity of the pyran 
group to the decalin ring system consisting of C4, C5, C19–C26 via the acetal in para-position to the 
ester/amide junction was detected by bilateral HMBC correlations between carbons and protons C/H27 
and C/H23 (Figure 1). The so far described fragments are in agreement with the published structures of 
tetromycins [13].  
The main differences between tetromycins 1,  2, and 4 and their previously isolated congeners 
covered in a patent [13] lie in the presence of a double bond between C20 and C21 (instead of between 
C25 and C26 as stated for tetromycin C5) of the decalin ring system and the position of a methyl group 
at C21 instead of at C20. The following detailed NMR correlations accounting for these altered 
positions are exemplarily discussed for tetromycin 4 using selected key NMR interactions (Figure 2). 
HSQC spectra showed two diastereotopic protons H22 (δ 2.26, 1.95) attached to C22 (δ 39.7). Strong 
ROESY and COSY correlation of H22 (δ 2.26) to H23 (δ 3.39) and correlative coupling constants 
suggested a 
3J-coupling and a direct connection between C23 and C22. In the HMBC H22 (δ 1.95) 
correlates with a methyl carbon at δ 18.9 (C21′) and two vinylic carbons at δ 125.8 (C20) and 
140.4 (C21), the latter presumably carrying the methyl group in agreement with the higher shift and 
according to HMBC signals. Methyl protons H21′ (δ 1.69) showed three strong correlations, not only 
with vinylic carbons C21 and C20 but also with C22 suggesting again the positioning of the methyl 
group at C21 and not at C20 as described earlier [13]. This conclusion was further substantiated by  
a strong HMBC correlation of the vinylic proton H20 (δ 4.92) with C24 (δ 46.5). Closing the first  
six-membered ring of the decalin system, C24 is directly connected to C23 as evidenced by direct 
COSY interactions and HMBC correlations of H22 (δ 2.26) to C24. C24 also correlated with proton 
H26 (δ 2.09), which in turn showed HMBC correlation with C23 (δ 84.9), C25 (δ 37.8), C4 (δ 52.6) 
and C4′ (δ 15.6). Looking at the corresponding 
13C NMR shifts, no C-C double bond could be located 
in the second six-membered ring of the decalin system, specifically not between C25 and C26 as 
featured in the previously described compounds. HMBC, 
13C, and 
1H data confirmed this result. We 
have thus discovered a series of tetromycin derivatives possessing a double bond between C20 and 
C21 and a methyl group at C21. The remaining partial structures of compounds 1, 2, and 4 are in turn 
in accordance with the already published compounds.  Mar. Drugs 2011, 9  
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Figure 2. Selected 2D NMR correlations in decalin of tetromycin 4. 
 
Interestingly, tetromycin 3 exhibiting a molecular ion in the positive ESIMS spectrum at   
m/z 861.4062  [M + H]
+ corresponding to a molecular formula of C48H61O14 was found to be a 
completely new derivative. The differences are again found in the decalin ring system made of C4, C5, 
C19–C26 and additionally in the cyclohexene fragment (C12–C17) carrying the acid group at C14 
(Figure 3). As seen for tetromycins 1, 2, and 4, HSQC data of tetromycin 3 revealed two diastereotopic 
protons H22 (δ 1.93, 2.32) located at C22 (δ 34.1). HMBC correlation of C23 with H22 (δ 1.93) again 
accounted for the single bond between C23 and C22 as discussed before. However, in this compound 
C23 also shows strong HMBC correlation to vinylic proton H21 (δ 4.95), suggesting close proximity 
to the carbon at δ 120.3 (C21) which is a CH-unit according to DEPT data. H21 furthermore correlates 
with methyl group C20′ (δ 14.3), C19 (δ 42.1), and interestingly also with C27 (δ 103.1), which 
reinforces the proposition of assigning δ 120.3 to C21 instead of to C20 as was found in our other 
isolated compounds. Unobserved in tetromycins 1, 2 and 4, methyl group protons H20′ of 3 correlated 
with C20, C21, and also with C19 (δ 42.07), the bridge atom of both six-membered rings of the decalin 
system, leading to the undoubted conclusion about the methyl group position at C20. The second  
six-membered ring only features saturated carbon atoms as was discussed above. 
Figure 3. Selected 2D NMR correlations in decalin of tetromycin 3.  
 Mar. Drugs 2011, 9  
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All tetromycin derivatives possess a cyclohexene fragment made of C12–17, with C12 and C17 
being the bridge atoms to the adjacent ring systems and C14 carrying the acid functional group. There 
is a C–C-double bond present between C13 and C14 as was already described in the published patent. 
Bridge atom C12 in the published compounds and in our compounds 1, 2, 4, and 5 is a quaternary 
carbon carrying methyl group C12′ (see Table 1 for respective shifts) as unmistakably revealed by 
COSY coupling of H11 and H12′, HMBC correlation of C12′ with H13 and H16 and those of H12′ 
with C13, C14, C17, C11, and C12 (Figure 4).  
Figure 4. Selected 2D NMR correlations in the cyclohexene fragment of tetromycin 4. 
 
After unambiguously confirming all positions of the cyclohexene carbons of tetromycin 3, none of 
the named correlations to a methyl group could be found. Furthermore, C12 showed a lower shift than 
in the other compounds and appeared as a CH in the DEPT spectrum. The loss of the methyl group at 
C12 was in accordance with the observed lower molecular mass, also indicating a formal loss of a 
CH2-fragment compared to the other compounds. We therefore report the discovery of the new 
tetromycin derivative (3) featuring a double bond between C20 and C21, a methyl substituent at C20, 
and hydrogen at C12. Lastly, compound 5 was found to be identical with tetromycin B [6] with   
m/z 557.3229 [M + Na]
+ corresponding to a molecular formula of C34H46O5. Figure 5 shows the 
structures of tetromycins 1–4 and tetromycin B (5). 
Figure 5. Structures of tetromycins 1–4 and tetromycin B (5). 
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Figure 5. Cont. 
 
2.2. Antiparasitic Activities 
The compounds were tested against the parasites Leishmania major and Trypanosoma brucei subsp. 
brucei and for cytotoxicity against 293T kidney epithelial cells and J774.1 macrophages (Table 2). 
Anti-Leishmania activity was only found for tetromycin 3. All five compounds exhibited   
anti-Trypanosoma activities at both 48 and 72 h time points as judged by IC50 values below 100 µM. 
The compounds also showed cytotoxic activities with IC50 < 100 µM against the kidney cell line and 
macrophages with the notable exception of tetromycin 1.  
Table 2. Antiparasitic and cytotoxic activities of tetromycins 1–4 and tetromycin B (5) 
(IC50, µM). 
Compound  L. major 
T. brucei brucei 
(48 h) 
T. brucei 
brucei (72 h) 
293T 
Kidney cells 
J774.1 
Macrophages 
1 >100 29.30  31.69  >100  >100 
2 >100 45.39  80.27  >100  50.21 
3 36.80 26.90  30.35  33.38  25.72 
4 >100 35.85  41.61  58.58  27.54 
5 >100 30.87  34.22  71.77  20.20 
2.3. Protease Inhibition 
The compounds were further subjected to protease inhibition assays with mammalian proteases 
cathepsin B and L, parasite cathepsin-L like proteases falcipain-2 (from P. falciparum) and rhodesain 
(from T. brucei rhodesiense), and with the coronaviral papain-like protease SARS-CoV PL
pro as well 
as with the coronaviral main protease SARS-CoV M
pro. Initial screening assays were performed at 
100 µM compound concentration. In a second step, compounds showing >50% enzyme inhibition at 
this concentration (compounds 3–5) were analyzed in detail. Substrate hydrolysis was monitored over 
10–40 min in the absence or presence of various inhibitor concentrations (seven inhibitor concentrations 
spanning from zero to total inhibition of the respective enzyme). Interestingly, inhibition of the cathepsin 
L-like proteases was observed to be time-dependent, while inhibition of cathepsin B and the 
coronaviral papain-like protease was not (Figure 6). All compounds were inactive or only weakly 
active (<10% inhibition at 100 µM) against the SARS-CoV M
pro. Mar. Drugs 2011, 9  
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Figure 6. Inhibition of rhodesain (left, time-dependent inhibition) and cathepsin B (right, 
non-time dependent inhibition) by tetromycin B (5) (inhibitor concentrations from top to 
bottom: 0, 1.67, 3.34, 6.68, 8.35, 10.0, 13.4, 16.7 µM). 
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For cathepsin B and SARS-CoV PL
pro, dissociation constants of enzyme-inhibitor complexes were 
calculated using the Dixon equation by fitting the residual enzyme activities against the inhibitor 
concentrations (Figure 7) and by correction to zero-substrate concentration (see Experimental Section). 
Figure 7. Inhibition of cathepsin B by tetromycin B (5). A Ki value of 1.50 µM was obtained. 
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In cases of time-dependent inhibition the pseudo-first order rate constants of inhibition kobs 
(obtained from the progress curves) were fitted against the inhibitor concentrations to obtain Ki, ki, and 
finally k2nd values (Figure 8, see Experimental Section for details). Mar. Drugs 2011, 9  
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Figure 8. Inhibition of rhodesain by compound 3; data from two independent assays are 
shown. The following inhibition constants were obtained: Ki = 2.1 µM; ki = 0.042 min
−1; 
k2nd = 38,100 M
−1 min
−1. 
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In order to ascertain if inhibition was competitive with respect to the substrates, we determined the 
Ki values for inhibition of rhodesain by tetromycin B (5) at three different substrate concentrations, 
and found no significant differences, indicating competitive inhibition. 
Interestingly, time-dependent inhibition was found only with cathepsin-L like enzymes, not with 
cathepsin B or the coronaviral protease PL
pro. This observed time-dependent inhibition could either be 
due to an irreversible inhibition mechanism resulting from covalent reaction of the reactive moiety of 
the inhibitors, the tetronic acid containing an α,β-unsaturated lactone ring, with the cysteine residue of 
the active sites of the target proteases, or to a slow-binding mechanism resulting from conformational 
changes of the enzyme-inhibitor complex. The reasons for the differences between cathepsin-L like 
proteases (mammalian cathepsin L, falcipain, rhodesain) and the others are not yet clear and will 
require more detailed studies with smaller synthetic derivatives containing the tetronic acid moiety. 
The inactivity against the SARS-CoV M
pro which is a cysteine protease differing from the   
other target proteases by the protonation state of its active site (Cys-SH/His instead of ion pair   
Cys-S
−/His-H
+) and its three-dimensional fold (similar to the serine protease chymotrypsin instead of 
papain-like fold) shows that the compounds are not unselective frequent hitters. It also supports the 
hypothesis that the compounds are covalent inhibitors of cathepsin-L like proteases, since the active 
centre of these proteases is more nucleophilic and thus better capable for reaction with the tetronic acid 
moiety. The inhibition constants (k2nd values and Ki values) do not differ largely between the three 
compounds indicating a common inhibition mechanism. Table 3 summarizes the inhibition constants. Mar. Drugs 2011, 9  
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Table 3. Inhibition of various cysteine proteases by tetromycins 3–4 and tetromycin B (5). 
Compound RD 
Ki (µM); 
k2nd (M
−1 min
−1) 
FP 
Ki (µM); 
k2nd (M
−1 min
−1) 
CL 
Ki (µM); 
k2nd (M
−1 min
−1) 
CB 
Ki (µM) 
SARS-CoV-PL
pro 
Ki (µM) 
3  2.1 ± 0.90; 
36,600 ± 1590 
1.65 ± 0.25; 
617 ± 9 
15.0 ± 1.95; 
14,977 ± 2005 
0.57 ± 0.04  n.d. 
4  4.00 ± 0.30; 
8354 ± 1562 
3.10 ± 0.20; 
1836 ± 108 
22.40 ± 0.80; 
14,700 ± 1000 
1.60 ± 0.10  40.00 ± 6.50 
5  0.62 ± 0.03; 
14,539 ± 1949 
1.42 ± 0.01; 
15,540 ± 1295 
32.50 ± 0.05; 
1576 ± 413 
1.59 ± 0.09  69.60 ± 7.20 
RD: rhodesain; FP: falcipain-2; CL: cathepsin L; CB: cathepsin B; n.d. not determined; Data presented are 
average values from at least two independent assays. 
3. Experimental Section  
3.1. General Experimental Procedures 
High resolution ESIMS analyses were performed on a Micromass Q-Tof micro mass spectrometer. 
NMR spectra were obtained on Varian INOVA 500 (
1H: 500 MHz, 
13C: 125 MHz) and Varian INOVA 
600 (
1H: 600 MHz, 
13C: 150 MHz) spectrometers with a 3 mm Nalorac MDBG probe and a 5 mm cold 
probe, respectively. UV spectra were acquired in spectroscopy grade MeOH using a Hewlett-Packard 
8452A diode array spectrophotometer. IR spectra were recorded using a JASCO FT/IR-400 
spectrophotometer. HPLC was performed on an Agilent 1100 system using a Luna C18 (Phenomenex, 
Inc.) (250 × 10 mm, 5 μm) column. 
3.2. Biological Material 
Streptomyces axinellae strain Pol001
T was cultivated from the Mediterranean sponge 
Axinella polypoides [10]. The sponge was collected by scuba diving offshore from Banyuls-sur-Mer, 
France (GPS: 42°29′ N 03°08′E). Streptomyces axinellae strain Pol001
T is deposited at the Deutsche 
Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ 41948T) and the Collection de 
l’Institut Pasteur (CIP 109838T). 
3.3. Extraction and Isolation 
The bacterial strain was grown on 200 MS [11] agar plates at 30 °C for seven days. Mycelial mass 
together with the agar were cut into small pieces and macerated overnight with sufficient volume of 
ethyl acetate to fully submerge the biomass. The resulting solution was filtered and maceration with 
ethyl acetate was repeated. Both filtrates were combined and dried by rotary evaporation. The isolation 
of the compounds was carried out by semi-preparative HPLC using H2O + 0.1% TFA (A) and CH3CN 
(B) as the solvents and the following gradient: flow 4.5 mL/min; 0–10 min 90% B, 11–15 min 100% B 
to yield five compounds: tetromycin 1 (1, 2.7 mg, Rt = 5.94 min); tetromycin 2 (2, 4.4 mg,   
Rt = 7.75 min); tetromycin 3 (3, 2.2 mg, Rt = 9.67 min); tetromycin 4 (4, 4.4 mg, Rt = 12.24 min); 
tetromycin B (5, 2.1 mg, Rt = 17.47 min). Mar. Drugs 2011, 9  
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Tetromycin 1 (1): light yellow amorphous solid; [α]
20
D −40.2 (c 1.92, MeOH); UV (MeOH) λmax 
(log ε) 210 (1.41), 244 (0.77), 268 (0.54); 
1H and 
13C NMR data, see Table 1; ESIMS m/z 910.4388  
[M + Na]
+ (calcd for C50H65NO13Na, 910.4354). 
Tetromycin 2 (2): light yellow amorphous solid; [α]
20
D −38.8 (c 2.50, MeOH); UV (MeOH) λmax 
(log ε) 212 (1.49), 242 (0.70), 268 (0.54); 
1H and 
13C NMR data, see Table 1; ESIMS m/z 911.4232  
[M + Na)]
+ (calcd for C50H64O14Na, 911.4219). 
Tetromycin 3 (3): light yellow amorphous solid; [α]
20
D −47.7 (c 3.00, MeOH); UV (MeOH) λmax 
(log ε) 214 (1.60), 244 (0.72), 266 (0.85); 
1H and 
13C NMR data, see Table 1; ESIMS m/z 861.4062  
[M + H]
+ (calcd for C48H61O14, 861.4062). 
Tetromycin 4 (4): light yellow amorphous solid; [α]
20
D −44.1 (c 3.83, MeOH); UV (MeOH) λmax 
(log  ε) 214 (1.84), 246 (0.79), 266 (1.03); 
1H and 
13C data, see Table 1; ESIMS m/z 897.4066   
[M + Na]
+ (calcd for C49H62O14Na, 897.4037). 
Tetromycin B (5): light yellow amorphous solid; [α]
20
D  −12.0 (c 1.83, MeOH); UV (MeOH)   
λmax (log ε) 210 (1.42), 244 (0.59), 268 (0.55); ESIMS m/z 557.3229 [M + Na]
+ (calcd for   
C34H46O5Na, 557.3243). 
3.4. Antiparasitic Activity Assays 
Leishmania major promastigotes were seeded at a cell density of 1 × 10
7 cells/mL into 96-well 
plates in complete medium (RPMI with NaHCO3, 10% FCS, 2 mM glutamine, 10 mM Hepes pH 7.2, 
100 U/mL penicillin, 50 µg/mL gentamicin, 50 mM 2-mercaptoethanol) without phenol red (200 mL), 
in the absence or presence of different concentrations of the compounds. These were then incubated 
for 24 h at 26 °C, 5% CO2 and 95% humidity. Following the addition of 20 µL of Alamar Blue, the 
plates were incubated again and the optical densities (ODs) measured 24 and 48 h later with an 
enzyme-linked immunosorbent assay (ELISA) reader (Multiskan Ascent, Germany) using a test 
wavelength of 540 nm and a reference wavelength of 630 nm. Absorbance in the absence of 
compounds was set as 100% of growth. Amphotericin B was used as a reference compound and 
positive control. The effects of cell density, incubation time and the concentration of DMSO were 
examined in control experiments. The final concentration of DMSO in the medium never exceeded  
1% vol/vol and had no effect on the proliferation of extracellular or intracellular parasites. For every 
experiment, each drug concentration was assayed in duplicate wells [14]. 
Trypomastigote forms of Trypanosoma brucei subsp. brucei laboratory strain TC 221 were cultured 
in complete Baltz medium [80 mL Baltz medium basic solution, 0.8 mL 2-mercaptoethanol stock 
solution (20 mM), 0.8 mL penicillin/streptomycin (10,000 U/mL), 16 mL FCS (inactivated for 30 min 
at 56 °C)]. Baltz medium basic solution is composed of the following: 500 mL MEM with Earle’s salts 
and  L-glutamine, 3 g Hepes, 0.5 g monohydrate glucose, 0.110 g sodium pyruvate, 0.007 g 
hypoxanthine, 0.002 g thymidine, 0.0107 g adenosine, 0.0141 g bathocuproinedisulfonic acid 
disodium salt, 0.146 g glutamine, 5 mL sterile non-essential amino acid concentrate (100×, pH 7.5). A 
defined number of parasites (10
4 trypanosomes per mL) in test chambers of 96-well plates were 
exposed to various concentrations of the test substances (dissolved in DMSO) to make a final volume 
of 200 µL in duplicate. Positive (trypanosomes in culture medium) and negative controls (test Mar. Drugs 2011, 9  
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substance without trypanosomes) were run simultaneously with each plate. The plates were then 
incubated at 37 °C in an atmosphere of 5% CO2 for a total time period of 72 h. After 24 h, 20 µL of 
Alamar Blue were added. The activity of the test substances was measured by light absorption using 
MR 700 Microplate Reader at a wavelength of 550 nm with a reference wavelength of 630 nm. The 
first reading was done at 48 h and subsequently at 72 h. The effect of the test substances was 
quantified in IC50 values by linear interpolation of three independent measurements [15]. 
3.5. Cytotoxicity Assays 
J774.1 macrophages were cultured in complete medium (RPMI with NaHCO3, 10% FCS, 2 mM 
glutamine, 10 mM Hepes pH 7.2, 100 U/mL penicillin, 50 µg/mL gentamicin, 50 M 2-mercaptoethanol) 
without phenol red in the absence or presence of increasing concentrations of the compounds at a cell 
density of 1 × 10
5 cells/mL (200 µL) for 24 h at 37 °C, 5% CO2 and 95% humidity. Following the 
addition of 20 µL of Alamar Blue, the plates were incubated and the ODs measured at 24, 48 and 72 h. 
The same Alamar Blue assay previously described for Leishmania was followed. Kidney epithelial 
293T cells were tested in the same manner as the macrophages but using complete DMEM medium 
(4.5 g/L solution of DMEM high glucose solution with sodium pyruvate but without L-glutamine, FBS 
superior at final concentration of 20%, 200 mM L-glutamine 100×) and cell density (2 × 10
4 cells/mL).  
3.6. Protease Inhibition Assays 
The fluorometric enzyme assays were performed on a Cary Eclipse fluorescence spectrophotometer 
(Varian, Darmstadt, Germany) using a microplate reader (excitation 365 nm, emission 460 nm). 
Cathepsin B and L protease inhibition assays were performed at 25 °C in 50 mM Tris-HCl buffer  
pH 6.2, containing 5 mM EDTA, 2 mM DTT, 200 mM NaCl, 0.005% Brij 35 as described by   
Vicik et al. [16–19]. 
Assays with falcipain-2 and rhodesain were performed in 50 mM acetate buffer pH 5.5 with 5 mM 
DTT, 5 mM EDTA, 200 mM NaCl, and 0.005% Brij 35. The substrate (Cbz-Phe-Arg-AMC for all 
four enzymes) and inhibitor stock solutions were prepared in DMSO (10% final concentration) and 
were diluted with assay buffer. The final substrate concentrations for the inhibition assays were   
10.0 µM (RD), 25 µM (FP-2), 6.25 µM (CL), and 100 µM (CB).  
The fluorometric SARS-CoV PL protease inhibition assays were performed at 25 °C in a 20 mM 
Tris-HCl buffer pH 7.5, containing 0.1 mM EDTA, 1 mM DTT, 200 mM NaCl, and 0.005% Brij 35. 
The final substrate concentration (Z-Arg-Leu-Arg-Gly-Gly-AMC-acetate salt) was 50 µM. Assays with 
SARS-CoV main protease were done in 20 mM Tris buffer pH 7.5 with 0.1 mM EDTA, 1 mM DTT, and 
200 mM NaCl. The substrate used was Abz-Ser-Val-Thr-Leu-Gln-Ser-Tyr(NO2)-Arg, TFA salt (Abz, 
anthranilic acid) at 50 µM final substrate concentration (excitation 325 nm, emission 425 nm). 
First, compounds were tested at 100 µM final concentration. For compounds showing considerable 
inhibition at this concentration (>50%), inhibition kinetics were analyzed in detail. Progress curves of 
substrate hydrolysis in absence or presence of inhibitor were monitored over a period of 10–40 min. 
For compounds showing non-time dependent inhibition the residual enzyme activities vi  
(obtained from the slopes of the progress curves) were fit to the inhibitor concentrations using the 
Dixon equation vi = vo/(1 + I/Ki
app), and correction to zero substrate concentration by the   Mar. Drugs 2011, 9  
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Cheng-Prusoff equation [20,21] for competitive inhibitors: Ki = Ki
app/(1 + [S]/Km). For compounds 
showing time-dependent inhibition the progress curves were fit to the exponential equation:   
y = limit × (1 − exp(−kobs × t)) + offset yielding the pseudo-first order rates of inhibition kobs. These 
were then fit to the inhibitor concentrations with kobs = ki × I/(Ki
app + I) yielding ki and Ki
app; Ki
app 
values were corrected to zero substrate concentration by: Ki = Ki
app/(1 + [S]/Km) and k2nd was 
calculated from k2nd = (ki/Ki). The Km values used to correct Ki
app values were determined in previous 
work: 0.9 µM (RD), 21.5 (FP-2), 6.5 (CL), 150 (CB), 850 (SARS-CoV PL
pro). The program GraFit 
(Erithacus Software Ltd., version 5.0.13) was used to calculate the inhibition constants.  
4. Conclusions 
These results presented herein highlight the importance of marine actinomycetes for drug discovery, 
as shown here by the identification of four structurally new tetromycin derivatives and a previously 
known compound, tetromycin B, from the marine sponge-derived isolate, Streptomyces axinellae. 
Antiparasitic activities against the causative agent of African sleeping disease, Trypansoma brucei, 
were reported. Furthermore, the compounds showed time-dependent inhibition of cathepsin L-like 
proteases with Ki values in the low micromolar range.  
The selectivity for cathepsin-like enzymes gives a good starting point for further studies with the 
aim to elucidate the moiety of the inhibitors responsible for inhibition (probably the tetronic acid 
moiety), to improve selectivity between mammalian and parasite enzymes, which may lead to less 
cytotoxicity, and to enhance inhibition potency. Furthermore, additional targets within the parasites, 
have to be taken into account. In Trypanosoma brucei, e.g., the cathepsin-B like protease TbCatB is 
also known to be essential for the parasite’s life cycle, and activity against this protease could 
contribute to the antiparasitic activities of the compounds. Finally, future work will also address 
stereochemical aspects.  
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